HRP20030959A2 - - Google Patents

Info

Publication number
HRP20030959A2
HRP20030959A2 HR20030959A HRP20030959A HRP20030959A2 HR P20030959 A2 HRP20030959 A2 HR P20030959A2 HR 20030959 A HR20030959 A HR 20030959A HR P20030959 A HRP20030959 A HR P20030959A HR P20030959 A2 HRP20030959 A2 HR P20030959A2
Authority
HR
Croatia
Prior art keywords
disorders
azulenes
neurotransmitters
dibenzo
aza
Prior art date
Application number
HR20030959A
Other languages
English (en)
Inventor
Merep Mladen
Mesi Milan
Pe�i� Dijana
D�apo Iva
Original Assignee
Pliva-Istra�iva�ki institut d.o.o.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva-Istra�iva�ki institut d.o.o. filed Critical Pliva-Istra�iva�ki institut d.o.o.
Priority to HR20030959A priority Critical patent/HRP20030959A2/xx
Priority to JP2006540631A priority patent/JP2007512308A/ja
Priority to CA002546591A priority patent/CA2546591A1/en
Priority to ES04798733T priority patent/ES2289573T3/es
Priority to US10/595,938 priority patent/US20070111990A1/en
Priority to PCT/HR2004/000054 priority patent/WO2005049036A1/en
Priority to CNA2004800394544A priority patent/CN1901918A/zh
Priority to EP04798733A priority patent/EP1684766B1/en
Priority to AT04798733T priority patent/ATE365556T1/de
Priority to DE602004007289T priority patent/DE602004007289T2/de
Publication of HRP20030959A2 publication Critical patent/HRP20030959A2/xx
Priority to HK07101111A priority patent/HK1098670A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR20030959A 2003-11-21 2003-11-21 HRP20030959A2 (ko)

Priority Applications (11)

Application Number Priority Date Filing Date Title
HR20030959A HRP20030959A2 (ko) 2003-11-21 2003-11-21
PCT/HR2004/000054 WO2005049036A1 (en) 2003-11-21 2004-11-19 USE OF 3-AZA-1-OXA-DIBENZO [e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS
CA002546591A CA2546591A1 (en) 2003-11-21 2004-11-19 Use of 3-aza-1-oxa-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
ES04798733T ES2289573T3 (es) 2003-11-21 2004-11-19 Uso de 3-aza-1-oxa-dibenzo(e,h)azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trastornos del sistema nervioso central.
US10/595,938 US20070111990A1 (en) 2003-11-21 2004-11-19 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
JP2006540631A JP2007512308A (ja) 2003-11-21 2004-11-19 中枢神経系の疾患及び障害の治療及び予防用医薬製剤を製造するための３−アザ−１−オキサ−ジベンゾ［ｅ，ｈ］アズレン類の使用
CNA2004800394544A CN1901918A (zh) 2003-11-21 2004-11-19 3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
EP04798733A EP1684766B1 (en) 2003-11-21 2004-11-19 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS
AT04798733T ATE365556T1 (de) 2003-11-21 2004-11-19 Verwendung von 3-aza-aoxa-dibenzo(e,h)azulenen zur herstellung von pharmazeutischen formulierung für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
DE602004007289T DE602004007289T2 (de) 2003-11-21 2004-11-19 Verwendung von 3-aza-1-oxadibenzo(e,h)azulenen zur Herstellung von pharmazeutischen Formulierungen für die Behandlung und Prävention von Erkrankungen und Störungen des zentralen Nervensystems
HK07101111A HK1098670A1 (en) 2003-11-21 2007-01-31 Use of 3-aza-1-oxa-dibenzo Äe,hÜ azulenes for the manufacture of pharmaceutical formulations for thetreatment and prevention of central nervous syste m disease and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20030959A HRP20030959A2 (ko) 2003-11-21 2003-11-21

Publications (1)

Publication Number Publication Date
HRP20030959A2 true HRP20030959A2 (ko) 2005-10-31

Family

ID=34611163

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030959A HRP20030959A2 (ko) 2003-11-21 2003-11-21

Country Status (11)

Country Link
US (1) US20070111990A1 (ko)
EP (1) EP1684766B1 (ko)
JP (1) JP2007512308A (ko)
CN (1) CN1901918A (ko)
AT (1) ATE365556T1 (ko)
CA (1) CA2546591A1 (ko)
DE (1) DE602004007289T2 (ko)
ES (1) ES2289573T3 (ko)
HK (1) HK1098670A1 (ko)
HR (1) HRP20030959A2 (ko)
WO (1) WO2005049036A1 (ko)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711489A (en) * 1971-03-31 1973-01-16 Pfizer Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4198421A (en) * 1978-11-30 1980-04-15 E. I. Du Pont De Nemours And Company Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
ES2130135T3 (es) * 1990-01-11 1999-07-01 Upjohn Co Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central.
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
HRP20020304B1 (en) * 2002-04-10 2008-04-30 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof

Also Published As

Publication number Publication date
HK1098670A1 (en) 2007-07-27
CN1901918A (zh) 2007-01-24
JP2007512308A (ja) 2007-05-17
CA2546591A1 (en) 2005-06-02
EP1684766A1 (en) 2006-08-02
DE602004007289T2 (de) 2008-03-06
US20070111990A1 (en) 2007-05-17
WO2005049036A1 (en) 2005-06-02
EP1684766B1 (en) 2007-06-27
ES2289573T3 (es) 2008-02-01
DE602004007289D1 (de) 2007-08-09
ATE365556T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
TW200407305A (en) Novel compounds
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
TW200531689A (en) Therapeutic agents
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200635903A (en) Therapeutic agents
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
MX2007012374A (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
SE0203713D0 (sv) Novel compounds
TW200633986A (en) Therapeutic agents
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
TW200734324A (en) Therapeutic agents
HRP20030885A2 (en) USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
HRP20030956A2 (en) USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
HRP20030959A2 (ko)
HRP20030955A2 (en) USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030957A2 (en) USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HK1098668A1 (en) Use of 1,3-diaza-dibenzo Äe.hÜ azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
IL179030A0 (en) Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования
WO2004020455A3 (en) Genes involved in neuropsychiatric disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071018

Year of fee payment: 5

PNAN Change of the applicant name, address/residence

Owner name: GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O.,

ODBI Application refused